Government-Owned Inventions; Availability for Licensing, 12700-12701 [05-5081]
Download as PDF
<![CDATA[
12700
Federal Register / Vol. 70, No. 49 / Tuesday, March 15, 2005 / Notices
TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN1
No. of
Respondents
Guidance
1 There
1
Dated: March 9, 2005.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 05–5040 Filed 3–14–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
Circulatory System Devices Panel of
the Medical Devices Advisory
Committee; Notice of Meeting
Food and Drug Administration,
HHS.
ACTION:
Total Annual
Responses
2
Hours
per Respondent
2
Total Hours
30
60
are no capital costs or operating and maintenance costs associated with this collection of information.
The use of VMAC for resolving
scientific disputes represents a new
process for CVM. Although the
procedures for requesting dispute
resolution by a scientific advisory
committee as set forth in the final
guidance document are new, CVM
estimates that the number of
respondents who would submit requests
would not increase. The number of
hours per respondent (30) encompasses
a wide range depending on the dispute
involved. The estimate was based on
discussions with industry and is an
average of hours per respondent.
AGENCY:
Annual Frequency
per Response
Notice.
This notice announces a forthcoming
meeting of a public advisory committee
of the Food and Drug Administration
(FDA). The meeting will be open to the
public.
Name of Committee: Circulatory
System Devices Panel of the Medical
Devices Advisory Committee.
General Function of the Committee:
To provide advice and
recommendations to the agency on
FDA’s regulatory issues.
Date and Time: The meeting will be
held on April 22, 2005, from 8 a.m. to
4:30 p.m.
Location: Holiday Inn, Walker/
Whetstone Rooms, Two Montgomery
Village Ave., Gaithersburg, MD.
Contact Person: Geretta Wood, Center
for Devices and Radiological Health
(HFZ–450), Food and Drug
Administration, 9200 Corporate Blvd.,
Rockville, MD 20850, 301–443–8320,
ext. 143, or FDA Advisory Committee
VerDate jul<14>2003
15:31 Mar 14, 2005
Jkt 205001
Information Line, 1–800–741–8138
(301–443–0572 in the Washington, DC
area), code 3014512625. Please call the
Information Line for up-to-date
information on this meeting.
Agenda: The committee will hear a
presentation by the Office of
Surveillance and Biometrics outlining
their responsibility for the review of
postmarket study design. The committee
will also hear an update on the status of
recent devices brought before the
committee. The committee will discuss
and make recommendations on a
premarket notification submission for a
coronary proximal anastomosis device.
Background information for the topics,
including the agenda and questions for
the committee, will be available to the
public 1 business day before the
meeting on the Internet at https://
www.fda.gov/cdrh/panelmtg.html.
Procedure: Interested persons may
present data, information, or views,
orally or in writing, on issues pending
before the committee. Written
submissions may be made to the contact
person by April 7, 2005. Oral
presentations from the public will be
scheduled for approximately 30 minutes
at the beginning of committee
deliberations and for approximately 30
minutes near the end of the
deliberations. Time allotted for each
presentation may be limited. Those
desiring to make formal oral
presentations should notify the contact
person before April 7, 2005, and submit
a brief statement of the general nature of
the evidence or arguments they wish to
present, the names and addresses of
proposed participants, and an
indication of the approximate time
requested to make their presentation.
Persons attending FDA’s advisory
committee meetings are advised that the
agency is not responsible for providing
access to electrical outlets.
FDA welcomes the attendance of the
public at its advisory committee
meetings and will make every effort to
accommodate persons with physical
disabilities or special needs. If you
require special accommodations due to
a disability, please contact AnnMarie
Williams, Conference Management
Staff, at 240–276–0450, ext. 113, at least
7 days in advance of the meeting.
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
Notice of this meeting is given under
the Federal Advisory Committee Act (5
U.S.C. app. 2).
Dated: March 7, 2005.
Sheila Dearybury Walcoff,
Associate Commissioner for External
Relations.
[FR Doc. 05–5039 Filed 3–14–05; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, DHHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: (301)
496–7057; fax: (301) 402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Karyotypic Complexity as a
Determinant of Anti-Cancer Drug
Activity
Ilan R. Kirsch and Anna V. Roschke
(NCI).
U.S. Provisional Patent Application
filed 04 Feb 2005 (DHHS Reference
No. E–101–2005/0–US–01).
Licensing Contact: Michelle A. Booden;
301/451–7337;
boodenm@mail.nih.gov.
E:\FR\FM\15MRN1.SGM
15MRN1
Federal Register / Vol. 70, No. 49 / Tuesday, March 15, 2005 / Notices
The recent clinical introduction of
small molecule inhibitors that target
single molecules as effective anticancer
therapies underscores the potential of
patient specific therapeutic
interventions. However, the definition
of a cancer specific target need not be
a single transforming or survival-related
gene or gene product. Another targetable
and relatively irreversible cellular state
might be the complexity and instability
of the chromosomal complement of
cancer cells. Structural and numerical
chromosomal alterations are present in
most neoplasms and karyotypic
complexity is associated with a poor
clinical prognosis as well as aggressive
and distinctive histopathologic features.
The present invention describes
methods for the selecting candidate
compounds for evaluation for the
treatment of cancer by defining the
karyotypic complexity and
heterogeneity in human cancer cells
based on three components of genomic
anatomy: ploidy, numerical
chromosome changes, and structural
chromosome rearrangements. Measures
of complexity include the number of
chromosomal rearrangements present in
a cell line (structural complexity, SC )
and the number of chromosome
deviations from the ploidy level
(numerical complexity, NC). Measures
of cell-to-cell chromosomal variability,
which reflect the degree of ongoing
instability, include numerical
heterogeneity (NH) and structural
heterogeneity (SH). Utilizing the
methods claimed in the this application,
a number of chemical compounds were
identified and later determined to have
increased cytotoxicity toward cancer
cell lines with a specific karyotypic
complexity.
The positive correlations between
drug sensitivity and karyotypic
complexity and heterogeneity found in
this analysis (122 statistically significant
positive correlations) provide a distinct
opportunity to identify agents that are
more active against karyotypically
complex and chromosomally unstable
cancer cells. Such cells would typically
be found in the epithelial cancers,
which cause so much therapeutic
concern and frustration.
Inhibition of Human Papillomavirus
Type 16 and 18 E6 and E7 Oncogene
Expression by E6 and E7-Specific
siRNAs
Zhi-Ming Zheng (NCI).
DHHS Reference No. E–079–2005/0–
US–01.
Licensing Contact: Michelle A. Booden;
(301) 451–7337;
boodenm@mail.nih.gov.
VerDate jul<14>2003
15:31 Mar 14, 2005
Jkt 205001
Cervical infection with human
papillomaviruses (HPVs), such as
HPV16 and HPV18, is strongly
associated with development of cervical
cancer. Integration of the viral genomes
into the cervical cell genome is
characteristic of infection with these
HPVs. Thus, the majority of cervical
cancer cells isolated from patients carry
these viral genomes and express two
viral oncoproteins, E6 and E7, which
induce p53 and pRb degradation.
Importantly, expression of both E6 and
E7 oncogenes is essential for survival of
cervical cancer cells.
Small interfering RNA (siRNA) is
emerging as a powerful tool for gene
silencing and has much potential for
anticancer and antiviral applications.
The present invention describes a
method employing novel siRNA
sequences for inhibiting expression of
the E6 and E7 viral oncoproteins of HPV
16 and 18, which are required for
development and progression of HPV
mediated cervical cancer.
Since HPV 16 and HPV 18 are the
most prevalent HPV types inducing
cervical cancer in women, this
discovery may have a significant impact
on cervical cancer therapy. This
technology could also have additional
implications in variety of HPVassociated indications, such as
anogenital warts, bladder, and head and
neck carcinomas.
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors.
Biomarkers for Osteoarthritis
Shari M. Ling et al. (NIA).
U.S. Provisional Application No. 60/
602,334 filed 18 Aug 2004 (DHHS
Reference No. E–354–2004/0–US–01).
Licensing Contact: Marlene Shinn-Astor;
(301) 435–4426;
shinnm@mail.nih.gov.
Osteoarthritis is chronic, often
progressive and substantially disabling
condition that becomes more common
with advanced age. Osteoarthritis
commonly involves the knees, hands,
hips, neck and back resulting in pain
and limitations of movement.
Unfortunately clinically available
tests are neither capable of detecting
osteoarthritis early in its development,
nor sensitive enough to adequately
assess disease progression. A better
means of diagnosing early osteoarthritis
and its progression that can be used to
assess the response to therapeutic
treatments is needed. The currently
available laboratory techniques are
highly sensitive but either lack
specificity or require large volumes of
PO 00000
Frm 00057
Fmt 4703
Sfmt 4703
12701
sample. Rolling Circle Amplification
(RCA) is new technology that precisely
localizes unique signals arising from
single reporter molecules. RCA has been
incorporated into antibody-based
microarray system protein chips that
enable testing with high sensitivity and
specificity for hundreds of proteins
simultaneously, using small sample
volumes.
This invention describes a method of
using RCA technology for detecting the
expression of serum proteins that are
perturbed in osteoarthritis patients. The
results of this testing can be used to
identify proteins associated with
osteoarthritis presence, prediction of
osteoarthritis development and
prognosis, predict response to
osteoarthritis treatment and potentially
also identify future anti-osteoarthritic
drugs.
In addition to licensing, the
technology is available for further
development through collaborative
research opportunities with the
inventors.
Water-Soluble, Antineoplastic
Derivatives of Taxol
Rudiger D. Haugwitz et al. (NCI).
U.S. Patent 4,942,184 issued 17 Jul 1990
(DHHS Reference No. E–090–1987/0–
US–01).
Licensing Contact: John Stansberry; 301/
435–5236; stansbej@mail.nih.gov.
A new class of taxol derivatives offer
an improved method for treating certain
cancers. The use of taxol as an
antineoplastic agent has been limited
due to poor solubility in aqueous
solutions. These new taxol derivatives
have improved water solubility while
retaining the cytotoxic properties of the
parent compounds. Their method of
synthesis and use in treating cancer
patients are provided.
Dated: March 7, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–5081 Filed 3–14–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
National Institutes of Health,
Public Health Service, DHHS.
ACTION: Notice.
AGENCY:
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
E:\FR\FM\15MRN1.SGM
15MRN1
]]>Agencies
[Federal Register Volume 70, Number 49 (Tuesday, March 15, 2005)]
[NO]
[Pages 12700-12701]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-5081]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: (301) 496-7057; fax: (301) 402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Karyotypic Complexity as a Determinant of Anti-Cancer Drug Activity
Ilan R. Kirsch and Anna V. Roschke (NCI).
U.S. Provisional Patent Application filed 04 Feb 2005 (DHHS Reference
No. E-101-2005/0-US-01).
Licensing Contact: Michelle A. Booden; 301/451-7337;
boodenm@mail.nih.gov.
[[Page 12701]]
The recent clinical introduction of small molecule inhibitors that
target single molecules as effective anticancer therapies underscores
the potential of patient specific therapeutic interventions. However,
the definition of a cancer specific target need not be a single
transforming or survival-related gene or gene product. Another
targetable and relatively irreversible cellular state might be the
complexity and instability of the chromosomal complement of cancer
cells. Structural and numerical chromosomal alterations are present in
most neoplasms and karyotypic complexity is associated with a poor
clinical prognosis as well as aggressive and distinctive
histopathologic features.
The present invention describes methods for the selecting candidate
compounds for evaluation for the treatment of cancer by defining the
karyotypic complexity and heterogeneity in human cancer cells based on
three components of genomic anatomy: ploidy, numerical chromosome
changes, and structural chromosome rearrangements. Measures of
complexity include the number of chromosomal rearrangements present in
a cell line (structural complexity, SC ) and the number of chromosome
deviations from the ploidy level (numerical complexity, NC). Measures
of cell-to-cell chromosomal variability, which reflect the degree of
ongoing instability, include numerical heterogeneity (NH) and
structural heterogeneity (SH). Utilizing the methods claimed in the
this application, a number of chemical compounds were identified and
later determined to have increased cytotoxicity toward cancer cell
lines with a specific karyotypic complexity.
The positive correlations between drug sensitivity and karyotypic
complexity and heterogeneity found in this analysis (122 statistically
significant positive correlations) provide a distinct opportunity to
identify agents that are more active against karyotypically complex and
chromosomally unstable cancer cells. Such cells would typically be
found in the epithelial cancers, which cause so much therapeutic
concern and frustration.
Inhibition of Human Papillomavirus Type 16 and 18 E6 and E7 Oncogene
Expression by E6 and E7-Specific siRNAs
Zhi-Ming Zheng (NCI).
DHHS Reference No. E-079-2005/0-US-01.
Licensing Contact: Michelle A. Booden; (301) 451-7337;
boodenm@mail.nih.gov.
Cervical infection with human papillomaviruses (HPVs), such as
HPV16 and HPV18, is strongly associated with development of cervical
cancer. Integration of the viral genomes into the cervical cell genome
is characteristic of infection with these HPVs. Thus, the majority of
cervical cancer cells isolated from patients carry these viral genomes
and express two viral oncoproteins, E6 and E7, which induce p53 and pRb
degradation. Importantly, expression of both E6 and E7 oncogenes is
essential for survival of cervical cancer cells.
Small interfering RNA (siRNA) is emerging as a powerful tool for
gene silencing and has much potential for anticancer and antiviral
applications. The present invention describes a method employing novel
siRNA sequences for inhibiting expression of the E6 and E7 viral
oncoproteins of HPV 16 and 18, which are required for development and
progression of HPV mediated cervical cancer.
Since HPV 16 and HPV 18 are the most prevalent HPV types inducing
cervical cancer in women, this discovery may have a significant impact
on cervical cancer therapy. This technology could also have additional
implications in variety of HPV-associated indications, such as
anogenital warts, bladder, and head and neck carcinomas.
In addition to licensing, the technology is available for further
development through collaborative research opportunities with the
inventors.
Biomarkers for Osteoarthritis
Shari M. Ling et al. (NIA).
U.S. Provisional Application No. 60/602,334 filed 18 Aug 2004 (DHHS
Reference No. E-354-2004/0-US-01).
Licensing Contact: Marlene Shinn-Astor; (301) 435-4426;
shinnm@mail.nih.gov.
Osteoarthritis is chronic, often progressive and substantially
disabling condition that becomes more common with advanced age.
Osteoarthritis commonly involves the knees, hands, hips, neck and back
resulting in pain and limitations of movement.
Unfortunately clinically available tests are neither capable of
detecting osteoarthritis early in its development, nor sensitive enough
to adequately assess disease progression. A better means of diagnosing
early osteoarthritis and its progression that can be used to assess the
response to therapeutic treatments is needed. The currently available
laboratory techniques are highly sensitive but either lack specificity
or require large volumes of sample. Rolling Circle Amplification (RCA)
is new technology that precisely localizes unique signals arising from
single reporter molecules. RCA has been incorporated into antibody-
based microarray system protein chips that enable testing with high
sensitivity and specificity for hundreds of proteins simultaneously,
using small sample volumes.
This invention describes a method of using RCA technology for
detecting the expression of serum proteins that are perturbed in
osteoarthritis patients. The results of this testing can be used to
identify proteins associated with osteoarthritis presence, prediction
of osteoarthritis development and prognosis, predict response to
osteoarthritis treatment and potentially also identify future anti-
osteoarthritic drugs.
In addition to licensing, the technology is available for further
development through collaborative research opportunities with the
inventors.
Water-Soluble, Antineoplastic Derivatives of Taxol
Rudiger D. Haugwitz et al. (NCI).
U.S. Patent 4,942,184 issued 17 Jul 1990 (DHHS Reference No. E-090-
1987/0-US-01).
Licensing Contact: John Stansberry; 301/435-5236;
stansbej@mail.nih.gov.
A new class of taxol derivatives offer an improved method for
treating certain cancers. The use of taxol as an antineoplastic agent
has been limited due to poor solubility in aqueous solutions. These new
taxol derivatives have improved water solubility while retaining the
cytotoxic properties of the parent compounds. Their method of synthesis
and use in treating cancer patients are provided.
Dated: March 7, 2005.
Steven M. Ferguson,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 05-5081 Filed 3-14-05; 8:45 am]
BILLING CODE 4140-01-P
